CIK 0001544227 · Non-accelerated filer<br>Smaller reporting company
Tempest Therapeutics, Inc.
Sign in to watch- Ticker
- TPST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 451472564
- Phone
- 415-798-8589
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA, 94005
- Former names
- Millendo Therapeutics, Inc., OvaScience, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-08 | Versant Venture Capital VI, L.P. 10% owner | Sale | −400,000 | $1.35 | $540K | 597,940 |
| 2024-07-03 | Brady Stephen R President and CEO | Purchase | +35,000 | $2.11 | $74K | 46,376 |
| 2024-07-02 | Whiting Samuel Chief Medical Officer | Purchase | +4,672 | $2.13 | $10K | 9,573 |
| 2024-06-28 | Trojanowski Justin Corporate Controller | Purchase | +7,500 | $2.16 | $16K | 22,168 |
| 2024-06-13 | Pellizzari Christine A Director | Grant or award · Stock Option (right to buy) | +16,000 | 16,000 | ||
| 2024-06-13 | NICHOL GEOFFREY Director | Grant or award · Stock Option (right to buy) | +16,000 | 16,000 | ||
| 2024-06-13 | Simantov Ronit Director | Grant or award · Stock Option (right to buy) | +16,000 | 16,000 | ||
| 2024-06-13 | RAAB MICHAEL Director | Grant or award · Stock Option (right to buy) | +16,000 | 16,000 | ||
| 2024-01-03 | Brady Stephen R President and CEO | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-01-03 | Whiting Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-01-03 | Trojanowski Justin Principal Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +26,500 | 26,500 | ||
| 2024-01-03 | Maestas Nicholas VP of Strategy and Finance | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-10-11 | Brady Stephen R President and CEO | Grant or award · Employee Stock Option (right to buy) | +725,000 | 725,000 | ||
| 2023-10-11 | Trojanowski Justin Corporate Controller | Grant or award · Employee Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2023-10-11 | Whiting Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +325,000 | 325,000 | ||
| 2023-10-11 | Maestas Nicholas VP of Strategy and Finance | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2023-06-15 | RAAB MICHAEL Director | Grant or award · Stock Option (right to buy) | +8,200 | 8,200 | ||
| 2023-06-15 | NICHOL GEOFFREY Director | Grant or award · Stock Option (right to buy) | +8,200 | 8,200 | ||
| 2023-06-15 | Pellizzari Christine A Director | Grant or award · Stock Option (right to buy) | +8,200 | 8,200 | ||
| 2023-06-15 | Simantov Ronit Director | Grant or award · Stock Option (right to buy) | +8,200 | 8,200 |
Page 2 of 6 · 119 trades